Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

CYTOKINETICS, INC. (CYTK)
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
04/23CYTOKINETICS, INC. : quaterly earnings release
04/12CYTOKINETICS : to Announce First Quarter Results on April 26, 2018
AQ
04/11ICE BUCKET DOLLARS AT WORK : New Method Developed to Help Improve ALS Clinical T..
AQ
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
03/27CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Changes in Registrant&rs..
AQ
03/26CYTOKINETICS INC : Changes in Registrant's Certifying Accountant, Financial Stat..
AQ
03/06CYTOKINETICS : to Present at March Investor Conferences
AQ
03/05CYTOKINETICS : Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
Financials ($)
Sales 2018 24,6 M
EBIT 2018 -96,9 M
Net income 2018 -110 M
Finance 2018 171 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 8,74x
EV / Sales 2019 4,62x
Capitalization 386 M
Chart CYTOKINETICS, INC.
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | CYTK | US23282W1009 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 14,7 $
Spread / Average Target 106%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
John Tannahill Henderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.386
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998